
ParcelBio Unveils $13M Seed Round for Next-Gen mRNA Platform
ParcelBio has raised $13 million to develop its new mRNA platform, which may help make protein treatments last longer in the body. Other companies also recently raised funds for similar next-generation mRNA and RNA therapies that might work better or reach more tissues. The science behind these therapies suggests they can be made stronger or last longer using special RNA designs. The US FDA recently introduced new ways that could help these products get approved faster, but experts say safety and manufacturing still need careful review. Analysts suggest that the first long-term mRNA treatments may be approved for use as early as 2028, though this depends on continued positive safety results.












